AI-generated summary
The authors conducted a systematic review and meta-analysis of seven randomized clinical trials with 329 patients to assess photobiomodulation for oral mucositis caused by cancer treatment. They report a pooled risk ratio of 0.50 (95% CI 0.35-0.73) with moderate heterogeneity (I2 = 40%), and describe the authors' conclusion that the therapy is highly effective.
- Participants
- 329
- Studies included
- 7
- Who or what was studied
- Cancer patients receiving chemotherapy and/or radiotherapy who developed or were at risk of oral mucositis
- Wavelengths
- 635, 660, 980 nm
- Limits stated in the abstract
- The abstract reports moderate heterogeneity across studies, variable treatment protocols, and a limited number of included trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 635 to 980 nm, 660 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Oral mucositis, Photobiomodulation therapy, Photobiomodulation, Systematic review, Meta-analysis, Publication bias, Heterogeneity, Risk of bias. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.